Nifty
Sensex
:
:
10906.95
36386.61
1.75 (0.02%)
12.53 (0.03%)

Pharmaceuticals & Drugs

Rating :
67/99  (View)

BSE: 532296 | NSE: GLENMARK

640.40
-21.10 (-3.19%)
18-Jan-2019 | 3:52PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  659.90
  •  663.00
  •  635.00
  •  661.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  959374
  •  6143.83
  •  711.90
  •  493.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 18,082.75
  • 20.02
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 21,487.44
  • 0.31%
  • 3.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.54%
  • 2.88%
  • 9.33%
  • FII
  • DII
  • Others
  • 2.72%
  • 4.02%
  • 34.51%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.84
  • 8.83
  • 6.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.51
  • 8.17
  • 2.37

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.41
  • 8.19
  • 2.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.19
  • 30.06
  • 22.61

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.32
  • 5.95
  • 4.85

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.41
  • 15.89
  • 13.73

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
2,581.33
2,256.59
14.39%
2,165.62
2,363.00
-8.35%
2,279.82
2,457.18
-7.22%
2,203.66
2,535.01
-13.07%
Expenses
2,141.23
1,868.19
14.62%
1,818.73
1,785.55
1.86%
1,952.98
2,013.34
-3.00%
1,880.97
1,769.98
6.27%
EBITDA
440.11
388.40
13.31%
346.88
577.45
-39.93%
326.83
443.84
-26.36%
322.69
765.02
-57.82%
EBIDTM
17.05%
17.21%
16.02%
24.44%
14.34%
18.06%
14.64%
30.18%
Other Income
139.88
29.73
370.50%
138.22
15.29
803.99%
69.55
-51.29
-
-23.16
14.57
-
Interest
85.13
69.84
21.89%
79.01
70.86
11.50%
74.39
69.67
6.77%
70.47
61.74
14.14%
Depreciation
82.45
75.23
9.60%
79.38
77.73
2.12%
73.53
68.90
6.72%
75.38
62.53
20.55%
PBT
579.59
273.05
112.27%
326.70
444.14
-26.44%
248.47
173.03
43.60%
153.67
655.33
-76.55%
Tax
165.59
58.93
180.99%
93.71
110.76
-15.39%
96.84
-10.73
-
48.93
178.23
-72.55%
PAT
414.00
214.12
93.35%
232.99
333.38
-30.11%
151.63
183.76
-17.48%
104.74
477.10
-78.05%
PATM
16.04%
9.49%
10.76%
14.11%
6.65%
7.48%
4.75%
18.82%
EPS
14.67
7.59
93.28%
8.26
11.81
-30.06%
5.37
6.52
-17.64%
3.71
16.91
-78.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
9,230.43
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
2,949.07
2,480.46
2,086.48
Net Sales Growth
-3.97%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
36.34%
18.89%
18.88%
 
Cost Of Goods Sold
3,205.48
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
951.07
784.28
658.07
Gross Profit
6,024.95
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
1,998.00
1,696.18
1,428.41
GP Margin
65.27%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
67.75%
68.38%
68.46%
Total Expenditure
7,793.91
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
2,356.82
1,860.89
1,631.50
Power & Fuel Cost
-
137.47
127.02
120.47
109.11
93.50
80.13
0.00
0.00
31.86
25.55
% Of Sales
-
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
0%
1.28%
1.22%
Employee Cost
-
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
510.17
289.95
272.34
% Of Sales
-
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
17.30%
11.69%
13.05%
Manufacturing Exp.
-
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
40.76
142.80
156.13
% Of Sales
-
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
1.38%
5.76%
7.48%
General & Admin Exp.
-
805.17
1,022.89
491.20
253.29
859.67
678.94
1,331.99
854.82
268.51
258.24
% Of Sales
-
8.87%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
28.99%
10.83%
12.38%
Selling & Distn. Exp.
-
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
0.00
310.32
254.38
% Of Sales
-
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
0%
12.51%
12.19%
Miscellaneous Exp.
-
35.66
88.52
38.82
38.48
228.40
33.61
0.00
0.00
33.15
254.38
% Of Sales
-
0.39%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
0%
1.34%
0.33%
EBITDA
1,436.51
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
592.25
619.57
454.98
EBITDA Margin
15.56%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
20.08%
24.98%
21.81%
Other Income
324.49
91.40
37.37
20.00
6.88
11.48
10.75
18.17
144.41
50.45
179.26
Interest
309.00
285.57
237.32
178.88
190.15
188.59
160.01
146.57
160.46
165.50
145.72
Depreciation
310.74
301.88
264.37
234.28
300.41
216.79
127.01
97.88
94.68
120.61
102.68
PBT
1,308.43
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
481.54
383.90
385.84
Tax
405.07
315.46
382.68
300.94
334.07
151.27
110.72
23.78
23.70
52.87
75.41
Tax Rate
30.96%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
4.92%
13.77%
28.04%
PAT
903.36
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
453.20
324.47
191.66
PAT before Minority Interest
903.25
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
457.83
331.03
193.47
Minority Interest
-0.11
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
-4.63
-6.56
-1.81
PAT Margin
9.79%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
15.37%
13.08%
9.19%
PAT Growth
-25.24%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
1.58%
39.67%
69.29%
 
Unadjusted EPS
32.01
28.49
39.29
26.47
7.72
20.01
22.91
17.03
16.78
12.40
7.70

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
2,037.24
2,355.23
1,598.16
Share Capital
28.22
28.22
28.22
27.13
27.12
27.09
27.05
27.03
26.98
25.05
Total Reserves
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
2,010.21
2,328.25
1,573.10
Non-Current Liabilities
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
519.01
1,940.41
2,151.27
Secured Loans
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
617.07
241.41
382.65
Unsecured Loans
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
0.00
1,627.98
1,711.69
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
14.58
6.90
0.00
0.00
Current Liabilities
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
2,259.06
518.62
456.33
Trade Payables
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
657.41
379.27
343.48
Other Current Liabilities
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
109.80
119.38
96.41
Short Term Borrowings
295.04
187.19
787.42
347.60
353.32
367.82
687.46
1,480.23
0.00
0.00
Short Term Provisions
432.46
262.95
134.03
216.78
259.95
33.22
10.63
11.62
19.97
16.44
Total Liabilities
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
4,842.01
4,827.27
4,208.92
Net Block
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
2,066.62
1,787.31
1,566.24
Gross Block
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
2,383.39
2,175.54
1,838.58
Accumulated Depreciation
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
316.77
388.23
272.33
Non Current Assets
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
2,243.24
2,406.20
2,129.78
Capital Work in Progress
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
145.70
600.77
545.41
Non Current Investment
14.66
15.69
17.20
17.12
0.00
0.00
0.00
0.00
18.12
18.12
Long Term Loans & Adv.
119.78
98.94
69.99
468.16
33.39
36.52
0.00
0.00
0.00
0.00
Other Non Current Assets
0.56
0.13
0.16
0.27
20.33
22.00
33.23
30.92
0.00
0.00
Current Assets
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
2,598.77
2,421.07
2,079.14
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
807.01
708.46
630.23
Sundry Debtors
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
1,130.81
1,078.28
955.34
Cash & Bank
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
195.83
107.02
71.48
Other Current Assets
1,391.61
683.39
391.88
31.44
872.81
635.91
593.95
465.11
527.31
422.09
Short Term Loans & Adv.
580.83
590.22
594.89
742.94
768.44
540.03
518.90
322.39
527.31
422.09
Net Current Assets
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
339.71
1,902.45
1,622.81
Total Assets
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00
4,842.01
4,827.27
4,208.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
930.58
352.40
15.91
PBT
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
481.55
383.90
268.88
Adjustment
571.28
726.56
391.03
522.76
709.78
342.45
484.05
189.65
265.26
274.15
Changes in Working Capital
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
353.13
-209.36
-387.66
Cash after chg. in Working capital
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
1,024.34
439.80
155.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
-93.75
-87.40
-139.46
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
-367.27
-386.91
-950.16
Net Fixed Assets
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
-40.77
-52.58
406.38
Net Investments
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
-48.33
-755.29
-40.93
Others
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
-278.17
420.96
-1,315.61
Cash from Financing Activity
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
-435.61
70.05
849.23
Net Cash Inflow / Outflow
166.21
488.24
163.27
140.86
387.61
379.11
165.21
127.70
35.54
-85.02
Opening Cash & Equivalents
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
103.58
71.48
156.51
Closing Cash & Equivalent
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
107.02
71.48

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
182.62
159.16
128.59
65.74
109.99
102.01
88.77
75.38
87.28
63.79
ROA
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
9.47%
7.33%
5.42%
ROE
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
20.85%
16.75%
12.42%
ROCE
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
15.34%
13.88%
13.37%
Fixed Asset Turnover
1.80
2.03
1.96
1.90
1.83
1.79
1.60
1.29
1.25
1.43
Receivable days
94.95
97.29
119.39
125.97
115.37
104.99
107.78
136.71
148.42
151.98
Inventory Days
83.59
73.65
67.68
59.42
53.99
59.39
72.38
93.78
97.70
88.92
Payable days
96.28
101.59
117.03
95.22
83.15
68.48
108.47
106.73
68.48
62.10
Cash Conversion Cycle
82.26
69.35
70.04
90.17
86.21
95.91
71.69
123.76
177.63
178.80
Total Debt/Equity
0.90
1.05
1.10
2.13
1.10
1.00
0.93
1.03
0.79
1.31
Interest Cover
4.92
7.28
6.84
3.86
4.70
5.62
4.33
4.00
3.32
2.85

News Update


  • Glenmark Pharma’s Suisse arm enters into licensing agreement with Yuhan Corporation
    10th Jan 2019, 09:11 AM

    Under the terms of the agreement, Glenmark will be responsible for manufacturing and supply of the product

    Read More
  • Glenmark aims consolidated revenue growth of 12-15% over next 3-5 years
    9th Jan 2019, 10:09 AM

    This would be mainly on account of strengthening the current business of generics, branded generics, anticipated launch of dermatology etc.

    Read More
  • Glenmark Pharma transfers API business to Glenmark Life Sciences
    2nd Jan 2019, 09:20 AM

    This transfer was completed on December 31, 2018

    Read More
  • Glenmark Pharma forays into branded dermatology segment in US
    19th Dec 2018, 09:08 AM

    The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc.

    Read More
  • Glenmark Pharma presents new data on GBR 1302, HER2xCD3 Bispecific Antibody
    18th Dec 2018, 10:36 AM

    These Phase 1 data will inform dosing regimen optimization of GBR 1302

    Read More
  • Glenmark Pharma receives ANDA approval for Fluocinolone Acetonide Oil
    18th Dec 2018, 09:35 AM

    According to IQVIA sales data for the 12 month period ending October 2018, the DermaOtic Oil, 0.01% (Ear Drops) market achieved annual sales of approximately $18.1 million

    Read More
  • Glenmark Pharma’s arm gets USFDA’s approval for Hydrocortisone Valerate Ointment
    17th Dec 2018, 09:12 AM

    This is Glenmark’s first granted CGT product approved by the USFDA

    Read More
  • Glenmark Pharma receives tentative approval from USFDA for Clobetasol Propionate Foam
    26th Nov 2018, 09:17 AM

    The company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio

    Read More
  • Glenmark Pharma gets final approval from USFDA for Atovaquone Oral Suspension
    22nd Nov 2018, 09:28 AM

    According to IQVIA sales data, the Mepron Oral Suspension, 750 mg/5 mL market2 achieved annual sales of around $119.1 million

    Read More
  • Glenmark gets final approval from USFDA for Azelaic Acid Gel
    20th Nov 2018, 08:59 AM

    According to IQVIA sales data for the 12 month period ending September 2018, the Finacea Gel, 15% market achieved annual sales of approximately $64.1 million

    Read More
  • Glenmark Pharmaceuticals receives ANDA approval for Teriflunomide Tablets
    16th Nov 2018, 09:22 AM

    The company was one of the first ANDA applicants to submit a substantially complete ANDA for Teriflunomide Tablets, 7 mg and 14 mg

    Read More
  • Glenmark Pharmaceuticals’ Q2 consolidated net profit jumps 93%
    14th Nov 2018, 10:45 AM

    Total consolidated income of the company increased by 19.02% at Rs 2,721.21 crore for Q2FY19

    Read More
  • Glenmark Pharma - Quarterly Results
    13th Nov 2018, 19:49 PM

    Read More
  • Glenmark Pharma to launch phase 1 trial in solid tumors for GBR 1342
    9th Nov 2018, 08:58 AM

    The decision is driven by recent findings derived from a non-interventional human study

    Read More
  • Glenmark Pharma launches Nourkrin in Russia
    1st Nov 2018, 09:44 AM

    Nourkrin Woman and Nourkrin Man will be exclusively marketed in Russia by Glenmark Impex LLC

    Read More
  • Glenmark receives USFDA’s final approval for Fluocinolone Acetonide Topical Oil
    30th Oct 2018, 10:01 AM

    The company’s current portfolio consists of 141 products authorized for distribution in the US marketplace

    Read More
  • Glenmark receives ANDA approval for Fluocinolone Acetonide Topical Oil
    26th Oct 2018, 10:11 AM

    Glenmark’s current portfolio consists of 140 products authorized for distribution in the US marketplace and 60 ANDAs pending approval with the USFDA

    Read More
  • Glenmark to present encore data from Phase 2a in Las Vegas
    19th Oct 2018, 10:16 AM

    The poster, GBR 830 induces progressive and sustained improvements in atopic dermatitis skin biomarkers and clinical parameters

    Read More
  • Glenmark’s arm receives USFDA’s final approval for Hydrocortisone Valerate Cream
    15th Oct 2018, 11:33 AM

    According to IQVIA sales data for the 12-month period ending August 2018, the Westcort Cream, 0.2% market achieved annual sales of approximately $17.0 million

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.